Pharsight

Drug Patents Expiring in 2030

1. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(5 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(5 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(6 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(6 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(6 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(6 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(6 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Acetaminophen patents expiration

ACETAMINOPHEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration
Apr, 2030

(5 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ACETAMINOPHEN family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Acuvue Theravision With Ketotifen patents expiration

ACUVUE THERAVISION WITH KETOTIFEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962376 JOHNSON JOHNSON VISN Methods and ophthalmic devices used in the treatment of ocular allergies
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS;OPHTHALMIC

More Information on Dosage

ACUVUE THERAVISION WITH KETOTIFEN family patents

Family Patents

4. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8915888 SANOFI-AVENTIS US Dosing and drive mechanism for drug delivery device
Jun, 2030

(6 years from now)

US9981013 SANOFI-AVENTIS US Use of AVE0010 for the treatment of diabetes mellitus type 2
Aug, 2030

(6 years from now)

US10028910 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1-agonist and methionine
Nov, 2030

(6 years from now)

US9707176 SANOFI-AVENTIS US Pharmaceutical composition comprising a GLP-1 agonist and methionine
Nov, 2030

(6 years from now)

US9308329 SANOFI-AVENTIS US Medication delivery device and method for operating a medication delivery device
Dec, 2030

(6 years from now)

US8475414 SANOFI-AVENTIS US Medication delivery device and method for operating a medication delivery device
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

5. Afrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511198 MANNKIND Dry powder inhaler and system for drug delivery
Feb, 2030

(5 years from now)

US8485180 MANNKIND Dry powder drug delivery system
Mar, 2030

(5 years from now)

US8551528 MANNKIND Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(6 years from now)

US8778403 MANNKIND Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(6 years from now)

US8734845 MANNKIND Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(6 years from now)

US10201672 MANNKIND Dry powder inhaler and system for drug delivery
Aug, 2030

(6 years from now)

US10500159 MANNKIND Apparatus and method for cryogranulating a pharmaceutical composition
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder.; Administrat...

Dosage: POWDER;INHALATION

More Information on Dosage

AFREZZA family patents

Family Patents

6. Airsupra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2026

Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient

Market Authorisation Date: 10 January, 2023

Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

AIRSUPRA family patents

Family Patents

7. Akynzeo patents expiration

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559523 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 10, 2019

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 10 October, 2014

Treatment: Method of treating emesis; Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy...

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

Family Patents

8. Akynzeo patents expiration

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

9. Alecensa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-756) Nov 06, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
New Chemical Entity Exclusivity(NCE) Dec 11, 2020

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

10. Amondys 45 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028
New Chemical Entity Exclusivity(NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMONDYS 45 family patents

Family Patents

11. Amzeeq patents expiration

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

US8865139 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(6 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(6 years from now)

US10086080 JOURNEY Topical tetracycline compositions
Oct, 2030

(6 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring
Oct, 2030

(6 years from now)

US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(6 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's drug patent expiration?
More Information on Dosage

AMZEEQ family patents

Family Patents

12. Anjeso patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(6 years from now)

US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

Family Patents

13. Anoro Ellipta patents expiration

ANORO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(6 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(6 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

14. Apadaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9549923 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Jul, 2030

(6 years from now)

US9132125 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

US8748413 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2019

Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: TABLET;ORAL

More Information on Dosage

APADAZ family patents

Family Patents

15. Apriso patents expiration

APRISO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688 SALIX Compositions and methods for treatment of bowel diseases with granulated mesalamine
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 31, 2011

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of APRISO before it's drug patent expiration?
More Information on Dosage

APRISO family patents

Family Patents

16. Aptiom patents expiration

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

17. Aristada patents expiration

ARISTADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(6 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

Family Patents

18. Aristada Initio Kit patents expiration

ARISTADA INITIO KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(6 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

Family Patents

19. Armonair Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

20. Arnuity Ellipta patents expiration

ARNUITY ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-290) Mar 01, 2026
New Strength(NS) May 17, 2021
New Patient Population(NPP) May 17, 2021
New Product(NP) Aug 20, 2017

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

21. Atrovent Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(5 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ATROVENT HFA family patents

Family Patents

22. Aubagio patents expiration

AUBAGIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024
New Chemical Entity Exclusivity(NCE) Sep 12, 2017

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

23. Auryxia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387191 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)

US10300039 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-790) Nov 06, 2020

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

Family Patents

24. Avycaz patents expiration

AVYCAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
New Patient Population(NPP) Dec 20, 2025
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Indication(I-738) Jun 22, 2019

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

25. Besivance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Mar, 2030

(5 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2014

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

NCE-1 date: 28 May, 2013

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

BESIVANCE family patents

Family Patents

26. Bevespi Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(6 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2019

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

Family Patents

27. Bevyxxa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents

28. Beyaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 24, 2013
New Combination(NC) Sep 24, 2013

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: Treatment of mood changes and/or anxiety as symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's drug patent expiration?
More Information on Dosage

BEYAZ family patents

Family Patents

29. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(5 years from now)

USRE49556 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Feb, 2030

(5 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
New Indication(I-826) Apr 08, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

30. Breo Ellipta patents expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXO GRP LTD Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026
M(M-202) May 15, 2020
New Product(NP) May 10, 2016
New Chemical Entity Exclusivity(NCE) May 10, 2018
New Indication(I-708) Apr 30, 2018

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

31. Brexafemme patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2026
New Indication(I-903) Nov 30, 2025
Generating Antibiotic Incentives Now(GAIN) Jun 01, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 01 June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

Family Patents

32. Breztri Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(6 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(6 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(6 years from now)

US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BREZTRI AEROSPHERE family patents

Family Patents

33. Brilinta patents expiration

BRILINTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(5 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

34. Briviact patents expiration

BRIVIACT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 27, 2024
New Chemical Entity Exclusivity(NCE) May 12, 2021

Drugs and Companies using BRIVARACETAM ingredient

NCE-1 date: 12 May, 2020

Market Authorisation Date: 12 May, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage

BRIVIACT family patents

Family Patents

35. Bydureon patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

36. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025
M(M-240) Feb 15, 2022
New Product(NP) Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

37. Bydureon Pen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(6 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(6 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

38. Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(5 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
New Indication(I-854) Jan 22, 2024
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028
New Indication(I-873) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Indication(I-760) Dec 19, 2020
New Product(NP) Apr 25, 2019
New Indication(I-792) Jan 14, 2022

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

39. Caldolor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Nov 19, 2024
New Patient Population(NPP) May 11, 2026
New Product(NP) Jun 11, 2012
New Dosing Schedule(D-152) Nov 20, 2018

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

40. Cerdelga patents expiration

CERDELGA's oppositions filed in EPO
CERDELGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Aug 19, 2021
New Chemical Entity Exclusivity(NCE) Aug 19, 2019
Orphan Drug Exclusivity(ODE-73) Aug 19, 2021

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents

41. Children's Allegra Allergy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097 CHATTEM SANOFI Fexofenadine suspension formulation
Aug, 2030

(6 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of CHILDREN'S ALLEGRA ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ALLEGRA ALLERGY family patents

Family Patents

42. Children's Allegra Hives patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097 CHATTEM SANOFI Fexofenadine suspension formulation
Aug, 2030

(6 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of CHILDREN'S ALLEGRA HIVES before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ALLEGRA HIVES family patents

Family Patents

43. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

44. Cometriq patents expiration

COMETRIQ's oppositions filed in EPO
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11091439 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(5 years from now)

US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

US11091440 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-33) Nov 29, 2019
Orphan Drug Exclusivity(ODE) Nov 29, 2019
New Chemical Entity Exclusivity(NCE) Nov 29, 2017

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 29 November, 2012

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage

COMETRIQ family patents

Family Patents

45. Consensi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408837 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 31, 2021

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

How can I launch a generic of CONSENSI before it's drug patent expiration?
More Information on Dosage

CONSENSI family patents

Family Patents

46. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8916195 NALPROPION Sustained release formulation of naltrexone
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

47. Copaxone patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9402874 TEVA PHARMS USA Low frequency glatiramer acetate therapy
Aug, 2030

(6 years from now)

US8969302 TEVA PHARMS USA Low frequency glatiramer acetate therapy
Aug, 2030

(6 years from now)

US9155776 TEVA PHARMS USA Low frequency glatiramer acetate therapy
Aug, 2030

(6 years from now)

US8399413 TEVA PHARMS USA Low frequency glatiramer acetate therapy
Aug, 2030

(6 years from now)

US8232250 TEVA PHARMS USA Low frequency glatiramer acetate therapy
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 28, 2017
New Indication(I-594) Feb 27, 2012

Drugs and Companies using GLATIRAMER ACETATE ingredient

Market Authorisation Date: 20 December, 1996

Treatment: Method of treating ms by administering copaxone

Dosage: INJECTABLE;SUBCUTANEOUS

How can I launch a generic of COPAXONE before it's drug patent expiration?
More Information on Dosage

COPAXONE family patents

Family Patents

48. Copiktra patents expiration

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-208) Sep 24, 2025
Orphan Drug Exclusivity(ODE-209) Sep 24, 2025
New Chemical Entity Exclusivity(NCE) Sep 24, 2023

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

Family Patents

49. Cotellic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803839

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

50. Creon patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198871 ABBVIE Delayed release pancreatin compositions
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2014
M(M-93) Jul 29, 2019
New Indication(I-625) Apr 30, 2013

Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient

NCE-1 date: 30 April, 2013

Market Authorisation Date: 30 April, 2009

Treatment: Treatment of exocrine pancreatic insufficiency

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

CREON family patents

Family Patents

51. Cubicin patents expiration

CUBICIN's oppositions filed in EPO
CUBICIN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage

CUBICIN family patents

Family Patents

52. Cubicin Rf patents expiration

CUBICIN RF's oppositions filed in EPO
CUBICIN RF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN RF before it's drug patent expiration?
More Information on Dosage

CUBICIN RF family patents

Family Patents

53. Cycloset patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9895422 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US10688155 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9352025 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US8877708 VEROSCIENCE Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wher...

Dosage: TABLET;ORAL

More Information on Dosage

CYCLOSET family patents

Family Patents

54. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(5 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

55. Dextenza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(5 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-876) Oct 07, 2024
New Indication(I-800) Jun 20, 2022
New Product(NP) Nov 30, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents

56. Dovato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

57. Dsuvia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10896751 VERTICAL PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(5 years from now)

US11676691 VERTICAL PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(5 years from now)

US8574189 VERTICAL PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(5 years from now)

US8202535 VERTICAL PHARMS Small-volume oral transmucosal dosage forms
Oct, 2030

(6 years from now)

US8865743 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 02, 2021

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

DSUVIA family patents

Family Patents

58. Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169238 AZURITY Solid pharmaceutical composition
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

59. Ella patents expiration

ELLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159681 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(5 years from now)

US10772897 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(5 years from now)

US9283233 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(5 years from now)

US8512745 LAB HRA PHARMA Ulipristal acetate tablets
Jun, 2030

(6 years from now)

US8962603 LAB HRA PHARMA Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Jun, 2030

(6 years from now)

US8426392 LAB HRA PHARMA Method for providing emergency contraception
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-271) Jun 24, 2024
New Chemical Entity Exclusivity(NCE) Aug 13, 2015

Drugs and Companies using ULIPRISTAL ACETATE ingredient

NCE-1 date: 13 August, 2014

Market Authorisation Date: 13 August, 2010

Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; ...

Dosage: TABLET;ORAL

How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage

ELLA family patents

Family Patents

60. Entereg patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946262 CUBIST PHARMS Methods of preventing and treating gastrointestinal dysfunction
Feb, 2030

(5 years from now)

US8112290 CUBIST PHARMS Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Oct 18, 2016
New Chemical Entity Exclusivity(NCE) May 20, 2013

Drugs and Companies using ALVIMOPAN ingredient

NCE-1 date: 20 May, 2012

Market Authorisation Date: 20 May, 2008

Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery; Accelerating the time to upper and ...

Dosage: CAPSULE;ORAL

How can I launch a generic of ENTEREG before it's drug patent expiration?
More Information on Dosage

ENTEREG family patents

Family Patents

61. Epclusa patents expiration

EPCLUSA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(6 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
M(M-277) Apr 27, 2025
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL; TABLET;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

62. Erleada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc)

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

63. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7910610 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Method for administering pirfenidone to avoid reduced efficacy by d...

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

64. Eucrisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(5 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-191) Apr 03, 2026
New Chemical Entity Exclusivity(NCE) Dec 14, 2021
Pediatric Exclusivity(PED) Sep 23, 2023
New Patient Population(NPP) Mar 23, 2023

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents

65. Evomela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020363 ACROTECH BIOPHARMA Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(6 years from now)

US10864183 ACROTECH BIOPHARMA Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(6 years from now)

US10940128 ACROTECH BIOPHARMA Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 10, 2023
Orphan Drug Exclusivity(ODE-110) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

66. Exem Foam Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 07, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 08 November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents

67. Fabior patents expiration

FABIOR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688071 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

US10568859 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

US8808716 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 11, 2015

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

FABIOR family patents

Family Patents

68. Fanapt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Apr, 2030

(5 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype
Aug, 2030

(6 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Oct, 2030

(6 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-939) Apr 02, 2027
M(M-180) May 26, 2019
New Chemical Entity Exclusivity(NCE) May 06, 2014

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation...

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

69. Farxiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

70. Fiasp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324157 NOVO Preparation comprising insulin, nicotinamide and an amino acid
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

FIASP family patents

Family Patents

71. Fiasp Flextouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324157 NOVO Preparation comprising insulin, nicotinamide and an amino acid
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

72. Filspari patents expiration

FILSPARI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-389) Feb 17, 2030
New Chemical Entity Exclusivity(NCE) Feb 17, 2028

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 17 February, 2027

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: TABLET;ORAL

More Information on Dosage

FILSPARI family patents

Family Patents

73. Filsuvez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827214 CHIESI Use of an oleogel containing triterpene for healing wounds
Nov, 2030

(6 years from now)

US9352041 CHIESI Use of an oleogel containing triterpene for healing wounds
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2028
Orphan Drug Exclusivity(ODE-460) Dec 18, 2030

Drugs and Companies using BIRCH TRITERPENES ingredient

NCE-1 date: 19 December, 2027

Market Authorisation Date: 18 December, 2023

Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa

Dosage: GEL;TOPICAL

More Information on Dosage

FILSUVEZ family patents

Family Patents

74. Flolipid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597289 TCG FLUENT PHARMA Liquid oral simvastatin compositions
Feb, 2030

(5 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Market Authorisation Date: 21 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

FLOLIPID family patents

Family Patents

75. Fosrenol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(6 years from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(6 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: POWDER;ORAL

How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage

FOSRENOL family patents

Family Patents

76. Fyarro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206887 AADI Prion free nanoparticle compositions and methods of making thereof
Apr, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 22, 2024
Orphan Drug Exclusivity(ODE-386) Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FYARRO family patents

Family Patents

77. Gemtesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

GEMTESA family patents

Family Patents

78. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103669 VERO BIOTECH INC Nitric oxide therapies
Jun, 2030

(6 years from now)

US8607785 VERO BIOTECH INC Systems and devices for generating nitric oxide
Jul, 2030

(6 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

79. Genvoya patents expiration

GENVOYA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(5 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(5 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(5 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Dosing Schedule(D-173) Dec 10, 2021
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

80. Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

81. Gilotrif patents expiration

GILOTRIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(5 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(6 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025
Orphan Drug Exclusivity(ODE) Apr 15, 2023
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

82. Gimoti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334281 EVOKE PHARMA INC Nasal formulations of metoclopramide
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage

GIMOTI family patents

Family Patents